PIKing up and AKTing on Resistance Mutations in Osimertinib-Treated EGFR-Mutated NSCLC

被引：0
|
作者：
Vokes, Natalie I. [1 ,2 ]
Le, Xiuning [1 ]
Yap, Timothy A. [1 ,3 ,4 ,5 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Houston, TX USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase Clin Trials Program 1, Houston, TX USA
[4] Univ Texas MD Anderson Canc Ctr, Therapeut Discovery Div, Houston, TX USA
[5] Univ Texas MD Anderson Canc Ctr, Khalifa Inst Personalized Canc Therapy, Houston, TX USA
来源：
CLINICAL CANCER RESEARCH | 2024年 / 30卷 / 18期
关键词：
CELL LUNG-CANCER; PTEN EXPRESSION; IMPACT;
D O I：
10.1158/1078-0432.CCR-24-1188
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A recent study identified high rates of PI3K-AKT pathway mutations from the FLAURA and AURA3 osimertinib trials and pre-clinically validated that these mutations decreased osimertinib sensitivity in EGFR-mutated non-small cell lung cancer. The AKT inhibitor capivasertib was found to overcome this resistance, providing an important rationale for the development of AKT inhibitors in non-small cell lung cancer.
引用
收藏
页码：3968 / 3970
页数：3
相关论文
共 50 条
  • [1] Prognostic impact of bone metastases in osimertinib-treated patients with EGFR-mutated NSCLC
    Tanaka, Ichidai
    Gen, Soei
    Hori, Kazumi
    Morise, Masahiro
    Koyama, Junji
    Kodama, Yuta
    Matsui, Akira
    Miyazawa, Ayako
    Hase, Tetsunari
    Hibino, Yoshitaka
    Yokoyama, Toshihiko
    Kimura, Tomoki
    Yoshida, Norio
    Sato, Mitsuo
    Ishii, Makoto
    CANCER SCIENCE, 2025, 116 : 329 - 329
  • [2] Osimertinib in Resected EGFR-Mutated NSCLC
    Tsuboi, Masahiro
    Herbst, Roy S.
    Wu, Yi-Long
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (14): : 1341 - 1342
  • [3] Osimertinib with Chemotherapy in EGFR-Mutated NSCLC
    van Doorn-Khosrovani, Sahar Barjesteh van Waalwijk
    Badrising, Sushil K.
    Burgers, Sjaak
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (05): : 478 - 479
  • [4] Osimertinib in EGFR-Mutated Advanced NSCLC
    Yan, Kelvin
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (19): : 1863 - 1863
  • [5] Clinical outcomes in Black patients with EGFR-mutated NSCLC treated with osimertinib
    Belani, Neel
    Rizwan, Farsha
    Hasler, Jill
    Bauman, Jessica
    Mitchell, Khadijah
    Borghaei, Hossein
    Bodor, Joseph N.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2024, 33 (09)
  • [6] CNS efficacy of osimertinib in EGFR-mutated advanced NSCLC
    Gourd, Elizabeth
    LANCET ONCOLOGY, 2018, 19 (10): : E516 - E516
  • [7] Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC
    Planchard, D.
    Janne, P. A.
    Cheng, Y.
    Yang, J. C. -H.
    Yanagitani, N.
    Kim, S-W
    Sugawara, S.
    Yu, Y.
    Fan, Y.
    Geater, S. L.
    Laktionov, K.
    Lee, C. K.
    Valdiviezo, N.
    Ahmed, S.
    Maurel, J-M
    Andrasina, I
    Goldman, J.
    Ghiorghiu, D.
    Rukazenkov, Y.
    Todd, A.
    Kobayashi, K.
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (21): : 1935 - 1948
  • [8] Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
    Tsuboi, Masahiro
    Herbst, Roy S.
    John, Thomas
    Kato, Terufumi
    Majem, Margarita
    Grohe, Christian
    Wang, Jie
    Goldman, Jonathan W.
    Lu, Shun
    Su, Wu-Chou
    de Marinis, Filippo
    Shepherd, Frances A.
    Lee, Ki Hyeong
    Le, Nhieu Thi
    Dechaphunkul, Arunee
    Kowalski, Dariusz
    Poole, Lynne
    Bolanos, Ana
    Rukazenkov, Yuri
    Wu, Yi-Long
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (02): : 137 - 147
  • [9] Tracking of activating EGFR mutations predicts progression-free survival in advanced EGFR-mutated NSCLC patients treated with osimertinib
    Buder, A.
    Hochmair, M. J.
    Setinek, U.
    Filipits, M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [10] Osimertinib also improves overall survival in EGFR-mutated NSCLC
    Lichert, Frank
    PNEUMOLOGIE, 2024, 78 (03): : 143 - 143
12345